BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-15 08:58 |
BerGenBio ASA: Mandatory notification of trade by primary insiders and close as…
|
English | 2.6 KB | ||
| 2024-04-15 05:00 |
BerGenBio ASA: Last day of the last exercise period for warrants issued in conn…
|
English | 10.2 KB | ||
| 2024-04-15 05:00 |
BerGenBio ASA: Siste dag av den siste utøvelsesperioden for de frittstående teg…
|
English | 10.5 KB | ||
| 2024-04-08 05:15 |
BerGenBio ASA: Last day of trading in warrants
|
English | 9.0 KB | ||
| 2024-04-08 05:00 |
Mandatory notification of trade by related party to Primary Insiders
|
English | 145.3 KB | ||
| 2024-04-08 05:00 |
Mandatory notification of trade by related party to Primary Insiders
|
English | 1004 bytes | ||
| 2024-04-03 11:22 |
BerGenBio ASA: Information about the last exercise period for Warrants issued i…
|
English | 9.2 KB | ||
| 2024-04-02 06:50 |
BerGenBio ASA: Start av den siste utøvelsesperioden for de frittstående tegning…
|
Norwegian | 15.7 KB | ||
| 2024-04-02 06:50 |
BerGenBio ASA: Commencement of the last exercise period for warrants issued in …
|
English | 15.4 KB | ||
| 2024-04-02 05:55 |
BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representi…
|
English | 11.7 KB | ||
| 2024-03-27 14:59 |
BerGenBio ASA: Exercise price in the last exercise period for warrants issued i…
|
English | 9.3 KB | ||
| 2024-03-20 16:15 |
BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer …
|
English | 4.5 KB | ||
| 2024-03-04 06:00 |
BerGenBio to Participate in Carnegie Nordic Healthcare Seminar
|
English | 2.5 KB | ||
| 2024-02-19 16:58 |
BerGenBio ASA - Approval and publication of a prospectus supplement
|
English | 2.2 KB | ||
| 2024-02-14 06:00 |
BerGenBio's Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum
|
English | 972.0 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
